title: Multiple organ tuberculosis of lung, pleura, and peritoneum in ankylosing spondylitis during adalimumab therapy.
abstract: A case of multiple organ tuberculosis (TBc) involving lung, pleura, and peritoneum in a 39-year-old man with long-standing ankylosing spondylitis (AS) treated with adalimumab was presented. The relationship between antitumor necrosis factor-α (anti-TNF-α) therapy and TBc was also reviewed. This case illustrates that TBc can develop in multiple organs during adalimumab therapy, and thus, the awareness of serious complications of multiple organs and atypical extrapulmonary pattern of TBc during anti-TNF-α therapy needs to be increased.
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, San 2-20 Geumam-dong, Deokjin-gu, Jeonju, Jeonbuk 561-756, South Korea. ywhim@jbnu.ac.kr
authors.forename: Wan-Hee
authors.initials: WH
authors.lastname: Yoo
mesh_terms: D000068879:Adalimumab; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D000995:Antitubercular Agents / Q000627:therapeutic use; D057915:Drug Substitution; D004359:Drug Therapy, Combination; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification; D014395:Peritonitis, Tuberculous / Q000139:chemically induced* / Q000150:complications / Q000276:immunology; D013902:Radiography, Thoracic; D013167:Spondylitis, Ankylosing / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome; D014396:Tuberculosis, Pleural / Q000139:chemically induced / Q000150:complications / Q000276:immunology; D014397:Tuberculosis, Pulmonary / Q000139:chemically induced* / Q000150:complications / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000995:Antitubercular Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab